Alto Neuroscience, Inc. (ANRO) Cash Flow Statement
Alto Neuroscience, Inc. (ANRO) generated -$68.3M of operating cash flow over the twelve months to 2026-06-30, spent $556000 on capital expenditure and had free cash flow of -$68.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANROAlto Neuroscience, Inc.Follow ANRO — free
—
Price chart with a free account
- Market cap
- 862.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -47.4 | -51.8 | -68.3 | |
| Capital expenditure | 2.1 | 0.0 | -0.6 | |
| Free cash flow | -49.5 | -51.8 | -68.8 | |
| Stock-based compensation | 7.6 | 8.1 | — |
USD millions · SEC XBRL
Alto Neuroscience, Inc. — questions
- What is Alto Neuroscience, Inc.'s operating cash flow?
- -$68.3M over the twelve months to 2026-06-30.
- How much does Alto Neuroscience, Inc. spend on capital expenditure?
- $556000 over the twelve months to 2026-06-30.
- What is Alto Neuroscience, Inc.'s free cash flow?
- -$68.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Alto Neuroscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.